{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:31:43Z","timestamp":1791829903344,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01555-3","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:30:40Z","timestamp":1761147040000},"page":"3703-3716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase\u00a03 Clinical Trials of Patients with Vitiligo"],"prefix":"10.1007","volume":"15","author":[{"given":"David","family":"Rosmarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Zdybski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Amster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Feser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoceng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"9988","key":"1555_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384.","journal-title":"Lancet"},{"issue":"6","key":"1555_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1555_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1507\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1555_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"key":"1555_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","volume":"12","author":"F Qi","year":"2021","unstructured":"Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125.","journal-title":"Front Immunol"},{"issue":"2","key":"1555_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40257-022-00752-6","volume":"24","author":"KN Cunningham","year":"2023","unstructured":"Cunningham KN, Rosmarin D. Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors. Am J Clin Dermatol. 2023;24(2):165\u201386.","journal-title":"Am J Clin Dermatol"},{"key":"1555_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"15","key":"1555_CR8","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"5","key":"1555_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase\u00a03 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1555_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1\u00a0year. Am J Clin Dermatol. 2024;25(2):327\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"10244","key":"1555_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase\u00a02 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"issue":"16","key":"1555_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase\u00a03, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"},{"issue":"6","key":"1555_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.404","volume":"4","author":"JE Harris","year":"2024","unstructured":"Harris JE, Pandya AG, Lebwohl M, et al. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: a randomised controlled trial secondary analysis at 3\u00a0years. Skin Health Dis. 2024;4(6):e404.","journal-title":"Skin Health Dis"},{"issue":"3","key":"1555_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","volume":"140","author":"ML Frisoli","year":"2017","unstructured":"Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol. 2017;140(3):654\u201362.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1555_CR15","first-page":"e378","volume":"39","author":"K Ezzedine","year":"2024","unstructured":"Ezzedine K, Wolkerstorfer A, Wei S, Korba AA, Kornacki D, Rosmarin D. Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream. J Eur Acad Dermatol Venereol. 2024;39(4):e378\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1555_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040279","volume":"11","author":"HR Tsai","year":"2021","unstructured":"Tsai HR, Lu JW, Chen LY, Chen TL. Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. J Pers Med. 2021;11(4):279.","journal-title":"J Pers Med"},{"issue":"4","key":"1555_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase\u00a03 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"1555_CR18","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5243","volume":"103","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Van der Gang LF, Zuithoff NPA, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay registry. Acta Derm Venereol. 2023;103:adv00872.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1555_CR19","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2022.9396","volume":"14","author":"S Alharthi","year":"2022","unstructured":"Alharthi S, Turkmani MG, AlJasser MI. Acne exacerbation after tofacitinib treatment for alopecia areata. Dermatol Rep. 2022;14(2):9396.","journal-title":"Dermatol Rep"},{"issue":"12","key":"1555_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","volume":"159","author":"J Martinez","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(12):1339\u201345.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1555_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15688","volume":"35","author":"C Correia","year":"2022","unstructured":"Correia C, Antunes J, Filipe P. Management of acne induced by JAK inhibitors. Dermatol Ther. 2022;35(9):e15688.","journal-title":"Dermatol Ther"},{"issue":"8","key":"1555_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/jech-2014-205300","volume":"69","author":"RM Viner","year":"2015","unstructured":"Viner RM, Ross D, Hardy R, et al. Life course epidemiology: recognising the importance of adolescence. J Epidemiol Community Health. 2015;69(8):719\u201320.","journal-title":"J Epidemiol Community Health"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01555-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:12Z","timestamp":1763198532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01555-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01555-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Rosmarin is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; has served as a consultant, speaker, or investigator for AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant Sciences, Dermira, Dualitas, EMD Serono, Galderma, Incyte Corporation, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT Therapeutics, Recludix, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, Viela Bio, and Zura Bio. Amit G. Pandya has served as an investigator for Aclaris Therapeutics, Immune Tolerance Network, Incyte Corporation, and Pfizer; a consultant for AbbVie, Arcutis, Avita Medical, Chromaderm, Immune Tolerance Network, Incyte Corporation, Pfizer, TWi, Viela Bio, and Villaris; and holds stock options for Tara Medical and Zerigo Health. Thierry Passeron has received grants and\/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Eli Lilly, Galderma, Genzyme\/Sanofi, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Novartis, Pfizer, Sun Pharmaceuticals, Takeda, UCB, and Vyne Therapeutics; is the cofounder of NIKAIA Pharmaceuticals; and has patents on WNT agonists and GSK3b antagonists for repigmentation of vitiligo and on the use of CXCR3B blockers in vitiligo. Seth B. Forman has received honoraria, clinical research grants, or fees as a consultant, speaker, advisory board member, and\/or investigator for AbbVie, Aclaris Therapeutics, Asana BioSciences, AstraZeneca, Athenex, Celgene Corporation, Cutanea Life Sciences, Eli Lilly, Incyte Corporation, Innovaderm Research, Novartis, Pfizer, Promius Pharma, Regeneron, UCB, Valeant Pharmaceuticals North America, and Xbiotech. Jacek Zdybski has served as an investigator for Almirall, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte Corporation, Innovaderm, Pfizer, Regeneron, Sun Pharmaceuticals, and Syneos Health. Mark Amster has been a primary investigator and received revenue from Acrotech Biopharma, Amgen, Arcutis Biotherapeutics, Bausch Health, Biopharmex, Boehringer Ingelheim, Botanix Pharmaceuticals, Cara Therapeutics, Concert Pharmaceuticals, Dermavant, Dermira, DermTech, Dr. Reddys Laboratories, Eli Lilly, Foamix, Highlight Pharmaceuticals, Incyte Corporation, Janssen, Kademis Ltd, LEO Pharma, Mayne Pharma, Mitsubishi Tanabe Pharma, Novartis, Novella, Pfizer, RAPT Therapeutics, Trevi Therapeutics, UCB Biopharma, Ventyx Biosciences, Vitae Pharmaceuticals, and Xbiotech USA and has received honoraria as a consultant for AbbVie, Cara Pharmaceuticals, Incyte Corporation, and Janssen. Christina Feser has served as a speaker, consultant, advisory board member, and\/or investigator for AbbVie, Aclaris, Acrotech Biopharma, Almirall, Amgen, Arcutis, Bristol Myers Squibb, Castle Biosciences, Cutanea, Eli Lilly and Company, Incyte Corporation, Kymab, LEO Pharma, Merck, MoonLake, Nektar Therapeutics, Novan, Novartis, Paradigm Medical, ParaPro, Pfizer, Skin Life Science, SkinTech, Takeda, Technoderma, and Ventyx. Kim A. Papp has received honoraria and\/or research grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sandoz, Sanofi-Aventis\/Genzyme, Sun Pharmaceuticals, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab. Anthony Nuara has received research funding from AbbVie, Aclaris Therapeutics, AOBiome, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte Corporation, Novartis, and Pfizer and has served as a paid speaker and\/or consultant for AbbVie, Amgen, Castle Biosciences, Bristol Myers Squibb, Dermavant, Galderma, Incyte Corporation, Janssen, and Novartis. Deanna Kornacki, Shaoceng Wei, and Haobo Ren are employees and shareholders of Incyte Corporation. John E. Harris has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme\/Sanofi, Janssen, Pfizer, Rheos Medicines, Sun Pharmaceuticals, TeVido BioDevices, The Expert Institute, 3rd Rock Ventures, and Villaris Therapeutics; has served as an investigator for Aclaris Therapeutics, Celgene, Dermira, EMD Serono, Genzyme\/Sanofi, Incyte Corporation, LEO Pharma, Pfizer, Rheos Medicines, Stiefel\/GlaxoSmithKline, Sun Pharmaceuticals, TeVido BioDevices, and Villaris Therapeutics; holds equity in Aldena Therapeutics, NIRA Biosciences, Rheos Medicines, TeVido BioDevices, and Villaris Therapeutics; is a scientific founder of Aldena Therapeutics, NIRA Biosciences, and Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, and CXCR3 antibody depletion for treatment of vitiligo. Khaled Ezzedine has served as a consultant for AbbVie, Almirall, Bristol Myers Squibb, Incyte Corporation, La Roche-Posay, Lilly, Pfizer, Pierre Fabre Pharmaceuticals, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with Good Clinical Practice guidelines, provisions of the Declaration of Helsinki, and applicable regulations. Study protocols were approved by each site\u2019s institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}